Nephrotic syndrome(NS) is children's most frequent glomerular disease. Steroid therapy is the mainstream therapy for decades. However, many patients always suffer from many adverse effects of steroids, such as growth impacted, fat, and glaucoma, et al. Steroid-sparing therapy is urgent. Rituximab, as a chemical monoclonal antibody against the cluster of differentiation antigen 20(CD20), is demonstrated to be effective in frequent/dependent nephrotic syndrome(FRNS) in many clinical trials. It has also been reported to be effective in six adult NS patients. Rituximab mono-therapy in new-onset pediatric NS patients is still unclear. Our main objective is to evaluate Rituximab monotherapy (as first-line therapy) on children with new-onset nephrotic syndrome.
The main objective is to evaluate the effectiveness of Rituximab monotherapy versus steroid therapy on children with new-onset nephrotic syndrome within the 52-week follow-up.